1. Acknowledgments

   Acknowledgement to Referees 12 November 2013 Pages: 1083 - 1085

2. Search MEDLINE for Economic Evaluations: Tips to Translate an OVID Strategy into a PubMed One

   • Mattias Neyt
   • Patrice X. Chalon

   Commentary 08 November 2013 Pages: 1087 - 1090

3. Assessing the Cost Effectiveness of Pre-Exposure Prophylaxis for HIV Prevention in the US

   • Fred J. Hellinger

   Current Opinion 24 November 2013 Pages: 1091 - 1104

4. How to Include Informal Care in Economic Evaluations

   • Renske J. Hoefman
   • Job van Exel
   • Werner Brouwer

   Practical Application 12 November 2013 Pages: 1105 - 1119

   

5. Vemurafenib for the Treatment of Locally Advanced or Metastatic BRAF V600 Mutation-Positive Malignant Melanoma: A NICE Single Technology Appraisal

   • Sophie Beale
   • Rumona Dickson
   • Chris Proudlove

   Review Article 10 October 2013 Pages: 1121 - 1129

   

6. The Estimation of Utility Weights in Cost-Utility Analysis for Mental Disorders: A Systematic Review

   • Michael Sonntag
   • Hans-Helmut König
   • Alexander Konnopka

   Systematic Review 30 November 2013 Pages: 1131 - 1154

   

7. Cost Effectiveness of Medication Adherence-Enhancing Interventions: A Systematic Review of Trial-Based Economic Evaluations

   • Edwin J. M. Oberjé
   • Reina J. A. de Kinderen
   • Marijn de Bruin

   Systematic Review 13 November 2013 Pages: 1155 - 1168

   

8. A Closer Look at Decision and Analyst Error by Including Nonlinearities in Discrete Choice Models: Implications on Willingness-to-Pay Estimates Derived from Discrete Choice Data in Healthcare

   • Esther W. de Bekker-Grob
   • John M. Rose
   • Michiel C. J. Bliemer

   Original Research Article 01 November 2013 Pages: 1169 - 1183

9. Erratum to: Cost–Utility Analysis of Deferiprone for the Treatment of β-Thalassaemia Patients with Chronic Iron Overload: A UK Perspective

   • Anthony Bentley
   • Samantha Gillard
   • Fernando Tricta

   Erratum 05 November 2013 Pages: 1185 - 1186